Armas is launching its generic of Genentech’s Tarceva (erlotinib) tablets. The product is used as targeted therapy, indicated for patients with metastatic non-small cell lung cancer.
The product is available in 25-mg, 100-mg and 150-mg strengths. This is Armas' third oral solid to be added to their oncology portfolio.
Erlotinib has a market value of approximately $150 million annually, according to sales data.
"I am excited to announce our sixth product launch of 2019 and seventh overall. As evidenced by our rapidly growing product portfolio, I could not be more pleased with the efforts put forth by the Armas team, while still keeping our core values at the center of it all," said John Niemi, Armas president and CEO.